{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:28:33Z","timestamp":1760059713302,"version":"build-2065373602"},"reference-count":90,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>The incidence of pancreatic ductal adenocarcinoma (PDAC) is continuing to rise globally, while overall survival continues to be poor. Margin-negative (R0) surgical resection is essential to improve patient outcomes. With increasing understanding of the importance of anatomy and biology to establishing the resectability of PDAC, neoadjuvant therapy (NAT) has emerged as an important strategy to achieve an R0 resection, particularly for those with borderline resectable (BR-PDAC) and locally advanced disease (LA-PDAC). However, despite the multiple randomised controlled trials (RCTs) published in recent years, the optimum regime has yet to be fully established. The role of neoadjuvant chemoradiation therapy (CRT) remains controversial, possibly allowing for improved local disease control at a potential cost of interrupting systemic treatment. The emergence of stereotactic ablative radiotherapy (SABR), in place of conventional radiation therapy, improves patient tolerance of NAT and may improve local tumour control for patients with PDAC during limited fractions, minimising systemic therapy interruption. A particular niche for SABR may be as part of NAT for LA-PDAC, potentially converting a minority of patients with favourable biology to allow for resection. While pancreaticoduodenectomy can be technically challenging following NAT, there is no difference in the rate of major morbidity or mortality post operatively. Indeed, post-operative pancreatic fistula (POPF) rates may be lower following NAT. Overall, however, evidence for SABR in a neoadjuvant setting for BR- and LA-PDAC remains sparse.<\/jats:p>","DOI":"10.3390\/diseases13070214","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:18:11Z","timestamp":1751948291000},"page":"214","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Stereotactic Ablative Radiotherapy in Pancreatic Ductal Adenocarcinoma: A Review of Perioperative and Long-Term Outcomes"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7570-7022","authenticated-orcid":false,"given":"Robert Michael","family":"O\u2019Connell","sequence":"first","affiliation":[{"name":"Department of Hepatopancreaticobiliary and Transplant Surgery, St Vincent\u2019s University Hospital, Elm Park, Dublin 4, D04 W6N7 Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emir","family":"Hoti","sequence":"additional","affiliation":[{"name":"Department of Hepatopancreaticobiliary and Transplant Surgery, St Vincent\u2019s University Hospital, Elm Park, Dublin 4, D04 W6N7 Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bengtsson, A., Andersson, R., and Ansari, D. (2020). The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-73525-y"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/MPA.0b013e318258055c","article-title":"Japan Pancreatic Cancer Registry; 30th Year Anniversary: Japan Pancreas Society","volume":"41","author":"Egawa","year":"2012","journal-title":"Pancreas"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1053\/j.gastro.2023.01.022","article-title":"Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001\u20132018","volume":"164","author":"Abboud","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2468-1253(23)00039-0","article-title":"Cause for concern: The rising incidence of early-onset pancreatic cancer","volume":"8","author":"Hepatology","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Partyka, O., Pajewska, M., Kwa\u015bniewska, D., Czerw, A., Depta\u0142a, A., Budzik, M., Cipora, E., G\u0105ska, I., Gazdowicz, L., and Mielnik, A. (2023). Overview of Pancreatic Cancer Epidemiology in Europe and Recommendations for Screening in High-Risk Populations. Cancers, 15.","DOI":"10.3390\/cancers15143634"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e190020","DOI":"10.1148\/rycan.2020190020","article-title":"Hereditary and Sporadic Pancreatic Ductal Adenocarcinoma: Current Update on Genetics and Imaging","volume":"2","author":"Morani","year":"2020","journal-title":"Radiol. Imaging Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11182","DOI":"10.3748\/wjg.v20.i32.11182","article-title":"Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection. Review","volume":"20","author":"Becker","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101783","DOI":"10.1016\/j.bpg.2021.101783","article-title":"Hereditary pancreatic cancer","volume":"58\u201359","author":"Klatte","year":"2022","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1158\/0008-5472.CAN-03-3823","article-title":"Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds","volume":"64","author":"Klein","year":"2004","journal-title":"Cancer Res."},{"key":"ref_11","unstructured":"World Health Organization, and Regional Office for Europe (2022). WHO European Regional Obesity Report 2022."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MPA.0000000000000974","article-title":"Obesity and Pancreatic Cancer","volume":"47","author":"Xu","year":"2018","journal-title":"Pancreas"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semcancer.2023.11.002","article-title":"Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges","volume":"97","author":"Srilatha","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2337\/db16-1477","article-title":"Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer","volume":"66","author":"Andersen","year":"2017","journal-title":"Diabetes"},{"key":"ref_15","first-page":"788","article-title":"Bariatric surgery reduces the risk of pancreatic cancer in individuals with obesity before the age of 50 years: A nationwide administrative data study in France","volume":"49","author":"Bulseia","year":"2023","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e3844","DOI":"10.1002\/dmrr.3844","article-title":"Metabolic\u2014Bariatric Surgery Reduces Pancreatic Cancer Risk: A Meta-Analysis of Over 3.7 Million Adults, Independent of Type 2 Diabetes Status","volume":"40","author":"Angelidi","year":"2024","journal-title":"Diabetes\/Metab. Res. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bpg.2017.09.001","article-title":"Tobacco and alcohol as risk factors for pancreatic cancer","volume":"31","author":"Korc","year":"2017","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100078","DOI":"10.1016\/j.gloepi.2022.100078","article-title":"Alcohol consumption and incidence of pancreatic cancer","volume":"4","author":"Tverdal","year":"2022","journal-title":"Glob. Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Underwood, P.W., Herremans, K.M., Neal, D., Riner, A.N., Nassour, I., Hughes, S.J., and Trevino, J.G. (2023). Changing Practice Patterns and Improving Survival for Patients with Pancreatic Ductal Adenocarcinoma. Cancers, 15.","DOI":"10.3390\/cancers15184464"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/EDBK_175222","article-title":"Pancreatic Adenocarcinoma: Improving Prevention and Survivorship","volume":"37","author":"Sohal","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Heinrich, S., Besselink, M., Moehler, M., Van Laethem, J.-L., Ducreux, M., Grimminger, P., Mittler, J., Lang, H., Lutz, M.P., and Lesurtel, M. (2019). Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: International survey and case-vignette study. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5889-5"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.pan.2020.01.004","article-title":"Prospective assessment of resection margin status following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma after standardisation of margin definitions","volume":"20","author":"Pine","year":"2020","journal-title":"Pancreatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/SLA.0000000000005874","article-title":"The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment","volume":"279","author":"Leonhardt","year":"2024","journal-title":"Ann. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/annonc\/mdx180","article-title":"Borderline resectable pancreatic cancer: Conceptual evolution and current approach to image-based classification","volume":"28","author":"Gilbert","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1245\/s10434-013-2886-9","article-title":"BORDERLINE RESECTABLE PANCREATIC CANCER: Need for Standardization and Methods for Optimal Clinical Trial Design","volume":"20","author":"Katz","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1245\/s10434-020-09100-6","article-title":"Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria","volume":"28","author":"Anger","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/bjc.2017.349","article-title":"Lymph node metastases in resected pancreatic ductal adenocarcinoma: Predictors of disease recurrence and survival","volume":"117","author":"Rubinson","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.hpb.2019.01.012","article-title":"Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer","volume":"21","author":"Kato","year":"2019","journal-title":"HPB"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/bjs\/znad210","article-title":"Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials","volume":"110","author":"Doppenberg","year":"2023","journal-title":"Br. J. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Van Veldhuisen, E., Van Den Oord, C., Brada, L.J., Walma, M.S., Vogel, J.A., Wilmink, J.W., Del Chiaro, M., Van Lienden, K.P., Meijerink, M.R., and Van Tienhoven, G. (2019). Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers, 11.","DOI":"10.3390\/cancers11070976"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00423-023-02849-w","article-title":"First jejunal vein, jejunal trunk, and pancreatico-duodenectomy: Resolving the literature conundrum","volume":"408","author":"Desai","year":"2023","journal-title":"Langenbeck\u2019s Arch. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1245\/s10434-016-5373-2","article-title":"Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer","volume":"23","author":"Rombouts","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/archsurg.1992.01420110083017","article-title":"Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the Pancreas","volume":"127","author":"Evans","year":"1992","journal-title":"Arch. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","article-title":"Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials","volume":"160","author":"Janssena","year":"2022","journal-title":"Eur. J. Cancer (Oxf. Engl. 1990)"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Oba, A., Ho, F., Bao, Q.R., Al-Musawi, M.H., Schulick, R.D., and Chiaro, M.D. (2020). Neoadjuvant Treatment in Pancreatic Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00245"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e161137","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): A multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2\/3 Trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/SLA.0000000000005430","article-title":"Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM\/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01)","volume":"275","author":"Yamaguchi","year":"2022","journal-title":"Ann. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2024.03.013","article-title":"Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas","volume":"120","author":"Tchelebi","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/SLA.0000000000004669","article-title":"A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer","volume":"275","author":"Hewitt","year":"2022","journal-title":"Ann. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): A four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Endo, Y., Kitago, M., and Kitagawa, Y. (2024). Evidence and Future Perspectives for Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Scoping Review. Cancers, 16.","DOI":"10.3390\/cancers16091632"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13014-019-1254-8","article-title":"Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: Study protocol of a prospective, randomized phase II trial (BRPCNCC-1)","volume":"14","author":"Gao","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Janssen, Q.P., Van Dam, J.L., Bonsing, B.A., Bos, H., Bosscha, K.P., Coene, P.P.L.O., Van Eijck, C.H.J., De Hingh, I.H.J.T., Karsten, T.M., and Van Der Kolk, M.B. (2021). Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): Study protocol for a nationwide multicenter randomized controlled t. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08031-z"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Groot Koerkamp, B., Janssen, Q.P., Van Dam, J.L., Bonsing, B.A., Bos, H., Bosscha, K.P., Haberkorn, B.C.M., De Hingh, I.H.J.T., Karsten, T.M., and Van Der Kolk, M.B. (2023). LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial. Ann. Oncol., 34.","DOI":"10.1016\/j.annonc.2023.10.084"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lambert, A., Bouche, O., Ayav, A., Bachet, J.-B., Schwarz, L., Piessen, G., Vendrely, V., Laurent, V., Thibaudeau, E., and Miglianico, L. (2024). LBA62 Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS\/PRODIGE 44. Ann. Oncol., 35.","DOI":"10.1016\/j.annonc.2024.08.2304"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/fon.15.335","article-title":"The role of neoadjuvant therapy in pancreatic cancer: A review","volume":"12","author":"Russo","year":"2016","journal-title":"Future Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Wu, H.-Y., Tsou, H.-H., Lu, L.-S., Lee, H.-L., Chiou, J.F., and Ch\u2019ang, H.-J. (2025). Role of neoadjuvant chemo-radiotherapy for resectable and borderline resectable pancreatic adenocarcinoma\u2014A systematic review and meta-analysis. Int. J. Radiat. Oncol. Biol. Phys.","DOI":"10.1016\/j.ijrobp.2025.02.037"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.surg.2021.12.013","article-title":"Radiation therapy in borderline resectable pancreatic cancer: A review","volume":"172","author":"Turner","year":"2022","journal-title":"Surgery"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"101266","DOI":"10.1016\/j.adro.2023.101266","article-title":"Predictors of Acute and Late Toxicity in Patients Receiving Chemoradiation for Unresectable Pancreatic Cancer","volume":"8","author":"Das","year":"2023","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.4240\/wjgs.v15.i8.1663","article-title":"Radiation therapy prior to a pancreaticoduodenectomy for adenocarcinoma is associated with longer operative times and higher blood loss","volume":"15","author":"Aploks","year":"2023","journal-title":"World J Gastrointest. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.3748\/wjg.v29.i35.5094","article-title":"Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer","volume":"29","author":"Zhou","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jso.26735","article-title":"Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma","volume":"125","author":"Mcintyre","year":"2022","journal-title":"J. Surg. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e000929","DOI":"10.1136\/esmoopen-2020-000929","article-title":"Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: Oncological outcomes at a single academic centre","volume":"5","author":"Pizzo","year":"2020","journal-title":"ESMO Open"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/SLA.0000000000001850","article-title":"Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients","volume":"264","author":"Hackert","year":"2016","journal-title":"Ann. Surg."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","article-title":"Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection","volume":"270","author":"Gemenetzis","year":"2019","journal-title":"Ann. Surg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/bjs\/znac354","article-title":"Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: Meta-analysis","volume":"110","author":"Brown","year":"2022","journal-title":"Br. J. Surg."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Stoop, T.F., Seelen, L.W.F., Van \u2019TLand, F.R., Van Der Hout, A.C., Scheepens, J.C.M., Ali, M., Stiggelbout, A.M., Van Der Kolk, B.M., Bonsing, B.A., and Lips, D.J. (2025). Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): Study protocol. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13554-w"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2006.09.7469","article-title":"Stereotactic body radiation therapy in multiple organ sites","volume":"25","author":"Timmerman","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2020.01.007","article-title":"Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database","volume":"143","author":"Xiang","year":"2020","journal-title":"Radiother Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2014","journal-title":"Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.30856","article-title":"Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review","volume":"123","author":"Eskander","year":"2017","journal-title":"Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/cncr.30706","article-title":"Outcomes for Patients With Locally Advanced Pancreatic Adenocarcinoma Treated With Stereotactic Body Radiation Therapy Versus Conventionally Fractionated Radiation","volume":"123","author":"Zhong","year":"2017","journal-title":"Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Burko\u0148, P., Trna, J., Sl\u00e1vik, M., N\u011bme\u010dek, R., Kazda, T., Posp\u00ed\u0161il, P., Dastych, M., Eid, M., Novotn\u00fd, I., and Proch\u00e1zka, T. (2022). Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer\u2014A Critical Review and Practical Consideration. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102480"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.prro.2017.10.001","article-title":"Results of a prospective phase 2 clinical trial of induction gemcitabine\/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma","volume":"8","author":"Quan","year":"2018","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.prro.2022.02.009","article-title":"Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial","volume":"12","author":"Hill","year":"2022","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.hpb.2020.11.004","article-title":"Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer","volume":"23","author":"Zakem","year":"2021","journal-title":"HPB"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.hpb.2023.04.019","article-title":"Neoadjuvant chemotherapy and stereotactic body radiation therapy for borderline resectable pancreas adenocarcinoma: Influence of vascular margin status and type of chemotherapy","volume":"25","author":"Palm","year":"2023","journal-title":"HPB"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.surg.2017.11.027","article-title":"Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy","volume":"163","author":"Blair","year":"2018","journal-title":"Surgery"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"101312","DOI":"10.1016\/j.adro.2023.101312","article-title":"Safety and Efficacy of Neoadjuvant SABR in Pancreatic Cancer: Effect of Magnetic Resonance Imaging\u2013Guided Respiratory-Gated Adaptive Radiation Therapy","volume":"9","author":"Song","year":"2024","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.pan.2021.02.024","article-title":"Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival","volume":"21","author":"Safi","year":"2021","journal-title":"Pancreatology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12957-024-03495-2","article-title":"Radicality and safety of total mesopancreatic excision in pancreatoduodenectomy: A systematic review and meta-analysis","volume":"22","author":"Belotto","year":"2024","journal-title":"World J. Surg. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijsu.2018.01.041","article-title":"The outcomes and complications of pancreaticoduodenectomy (Whipple procedure): Cross sectional study","volume":"52","author":"Karim","year":"2018","journal-title":"Int. J. Surg."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/OAS.S421494","article-title":"Risk factors for post-pancreaticoduodenectomy mortality: Identification and Mitigation","volume":"17","author":"Gazivoda","year":"2024","journal-title":"Open Access Surg."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jso.25183","article-title":"Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy","volume":"118","author":"Cools","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/jhbp.1052","article-title":"Estimation of the degree of surgical difficulty anticipated for pancreatoduodenectomy: Preoperative and intraoperative factors","volume":"29","author":"Kosaka","year":"2022","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.hpb.2020.03.007","article-title":"Neoadjuvant therapy for pancreatic cancer changes the composition of the pancreatic parenchyma","volume":"22","author":"Nahm","year":"2020","journal-title":"HPB"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1111\/ans.15885","article-title":"Impact of neoadjuvant therapy on post-operative pancreatic fistula: A systematic review and meta-analysis","volume":"90","author":"Kamarajah","year":"2020","journal-title":"ANZ J. Surg."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"547","DOI":"10.21037\/jgo.2016.03.15","article-title":"Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer","volume":"7","author":"Mellon","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.prro.2020.02.010","article-title":"The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma","volume":"10","author":"Koong","year":"2020","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clon.2023.11.041","article-title":"Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial","volume":"36","author":"Mou","year":"2024","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Doppenberg, D., Besselink, M.G., Van Eijck, C.H.J., Intven, M.P.W., Koerkamp, B.G., Kazemier, G., Van Laarhoven, H.W.M., Meijerink, M., Molenaar, I.Q., and Nuyttens, J.J.M.E. (2022). Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): A nationwide multicenter randomized controlled trial according to a TwiCs design. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10419-4"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/SLA.0000000000005958","article-title":"Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)","volume":"278","author":"Snyder","year":"2023","journal-title":"Ann. Surg."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/7\/214\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:06:16Z","timestamp":1760033176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/13\/7\/214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":90,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["diseases13070214"],"URL":"https:\/\/doi.org\/10.3390\/diseases13070214","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}